These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 11462924)
41. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience. Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200 [TBL] [Abstract][Full Text] [Related]
42. Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles. Sasaki M; Nakanuma Y; Ho SB; Kim YS Am J Clin Pathol; 1998 Mar; 109(3):302-8. PubMed ID: 9495202 [TBL] [Abstract][Full Text] [Related]
43. Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Chia WK; Ong S; Toh HC; Hee SW; Choo SP; Poon DY; Tay MH; Tan CK; Koo WH; Foo KF Ann Acad Med Singap; 2008 Jul; 37(7):554-8. PubMed ID: 18695766 [TBL] [Abstract][Full Text] [Related]
44. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429 [TBL] [Abstract][Full Text] [Related]
45. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Giuliani F; Gebbia V; Maiello E; Borsellino N; Bajardi E; Colucci G; Ann Oncol; 2006 Jun; 17 Suppl 7():vii73-7. PubMed ID: 16760299 [TBL] [Abstract][Full Text] [Related]
46. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Li S; Niu Z; Tian H; Zhang B; Wang F; Yi LH; Yu J Hepatogastroenterology; 2007; 54(73):218-23. PubMed ID: 17419264 [TBL] [Abstract][Full Text] [Related]
47. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Lee MA; Woo IS; Kang JH; Hong YS; Lee KS Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829 [TBL] [Abstract][Full Text] [Related]
48. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Rizell M; Andersson M; Cahlin C; Hafström L; Olausson M; Lindnér P Int J Clin Oncol; 2008 Feb; 13(1):66-70. PubMed ID: 18307022 [TBL] [Abstract][Full Text] [Related]
49. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814 [TBL] [Abstract][Full Text] [Related]
50. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402 [TBL] [Abstract][Full Text] [Related]
51. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater. Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR Tumori; 2013; 99(2):139-44. PubMed ID: 23748804 [TBL] [Abstract][Full Text] [Related]
52. [Two cases of curatively resected intrahepatic cholangiocellular carcinomas through effective response to neoadjuvant chemotherapy]. Kamo N; Mori A; Nitta T; Hatano E; Mitsuyoshi H; Ikeda K; Uemoto S Gan To Kagaku Ryoho; 2011 Feb; 38(2):305-8. PubMed ID: 21368501 [TBL] [Abstract][Full Text] [Related]
53. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. Poh SB; Bai LY; Chen PM Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261 [TBL] [Abstract][Full Text] [Related]
54. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. Zhu AX; Blaszkowsky LS; Ryan DP; Clark JW; Muzikansky A; Horgan K; Sheehan S; Hale KE; Enzinger PC; Bhargava P; Stuart K J Clin Oncol; 2006 Apr; 24(12):1898-903. PubMed ID: 16622265 [TBL] [Abstract][Full Text] [Related]
55. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521 [TBL] [Abstract][Full Text] [Related]
56. Review of gemcitabine in biliary tract carcinoma. Scheithauer W Semin Oncol; 2002 Dec; 29(6 Suppl 20):40-5. PubMed ID: 12577232 [TBL] [Abstract][Full Text] [Related]
57. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location. Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212 [No Abstract] [Full Text] [Related]
58. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Thongprasert S; Napapan S; Charoentum C; Moonprakan S Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284 [TBL] [Abstract][Full Text] [Related]
59. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548 [TBL] [Abstract][Full Text] [Related]
60. Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC). Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M Hepatogastroenterology; 2008; 55(85):1380-4. PubMed ID: 18795694 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]